Efficacy of aztreonam/avibactam against Stenotrophomonas maltophilia alone and in combination with tigecycline

Özlem Oyardı; Gülbeyaz Altunboğa; Fatıma Nur Olcay; Zayre Erturan

Article Details

Efficacy of aztreonam/avibactam against Stenotrophomonas maltophilia alone and in combination with tigecycline

Authors:

Özlem Oyardı | Gülbeyaz Altunboğa | Fatıma Nur Olcay | Zayre Erturan

Publisher:

Istanbul University

Main Topics:

Pharmacology and Pharmaceutical Sciences (Other)

Journal:

İstanbul Journal of Pharmacy Vol.54 Issue 3, pp.395-402

Document Type:

Article

Publication Date:

12/2024

Document Language:

English

Document ID (Org No.):

2001340675

pISSN:

2587-2087

Keywords:

Abstract:

 Background and Aims: Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen that threatens human and public health because of its widespread intrinsic and acquired antibiotic resistance. These bacteria become resistant to aztreonam by degrading it using the beta-lactamases. The aim of this study was to evaluate the effect of aztreonamavibactam on aztreonam resistance in clinical strains of S. maltophilia and to assess the synergistic potential of aztreonam in combination with tigecycline. Methods: Minimum Inhibitory Concentrations MICs of aztreonam, aztreonamavibactam, tigecycline, and doxycycline were determined using broth microdilution in sixty-six S. maltophilia isolates. Additionally, six isolates with the most common MICs of aztreonamavibactam against the strains, 2 μgml and 4 μgml were selected from among the sixty-six tested strains, and the effectiveness of the combination of aztreonamavibactam with tigecycline was determined using both the checkerboard test and the time-dependent killing method. Results: Aztreonamavibactam restored aztreonam activity in 96.9 of resistant S. maltophilia isolates. Half of the isolates were susceptible to tigecycline, whereas all were susceptible to doxycycline. The combination of aztreonamavibactam with tigecycline was found to have an additive effect against all isolates in the checkerboard experiment in which the activity of aztreonamavibactam in combination with tigecycline was investigated against six isolates. In the time-dependent killing experiment, the combination exerted a synergistic effect against two isolates. Conclusion: Aztreonamavibactam appears to be an important alternative for reversing aztreonam resistance in S. maltophilia. Additionally, tetracyclines, such as tigecycline and doxycycline, are highly effective against these bacteria. To confirm these promising findings, further in vitro, in vivo, and clinical studies are required.

 Background and Aims: Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen that threatens human and public health because of its widespread intrinsic and acquired antibiotic resistance. These bacteria become resistant to aztreonam by degrading it using the beta-lactamases. The aim of this study was to evaluate the effect of aztreonamavibactam on aztreonam resistance in clinical strains of S. maltophilia and to assess the synergistic potential of aztreonam in combination with tigecycline. Methods: Minimum Inhibitory Concentrations MICs of aztreonam, aztreonamavibactam, tigecycline, and doxycycline were determined using broth microdilution in sixty-six S. maltophilia isolates. Additionally, six isolates with the most common MICs of aztreonamavibactam against the strains, 2 μgml and 4 μgml were selected from among the sixty-six tested strains, and the effectiveness of the combination of aztreonamavibactam with tigecycline was determined using both the checkerboard test and the time-dependent killing method. Results: Aztreonamavibactam restored aztreonam activity in 96.9 of resistant S. maltophilia isolates. Half of the isolates were susceptible to tigecycline, whereas all were susceptible to doxycycline. The combination of aztreonamavibactam with tigecycline was found to have an additive effect against all isolates in the checkerboard experiment in which the activity of aztreonamavibactam in combination with tigecycline was investigated against six isolates. In the time-dependent killing experiment, the combination exerted a synergistic effect against two isolates. Conclusion: Aztreonamavibactam appears to be an important alternative for reversing aztreonam resistance in S. maltophilia. Additionally, tetracyclines, such as tigecycline and doxycycline, are highly effective against these bacteria. To confirm these promising findings, further in vitro, in vivo, and clinical studies are required.

 Background and Aims: Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen that threatens human and public health because of its widespread intrinsic and acquired antibiotic resistance. These bacteria become resistant to aztreonam by degrading it using the beta-lactamases. The aim of this study was to evaluate the effect of aztreonamavibactam on aztreonam resistance in clinical strains of S. maltophilia and to assess the synergistic potential of aztreonam in combination with tigecycline. Methods: Minimum Inhibitory Concentrations MICs of aztreonam, aztreonamavibactam, tigecycline, and doxycycline were determined using broth microdilution in sixty-six S. maltophilia isolates. Additionally, six isolates with the most common MICs of aztreonamavibactam against the strains, 2 μgml and 4 μgml were selected from among the sixty-six tested strains, and the effectiveness of the combination of aztreonamavibactam with tigecycline was determined using both the checkerboard test and the time-dependent killing method. Results: Aztreonamavibactam restored aztreonam activity in 96.9 of resistant S. maltophilia isolates. Half of the isolates were susceptible to tigecycline, whereas all were susceptible to doxycycline. The combination of aztreonamavibactam with tigecycline was found to have an additive effect against all isolates in the checkerboard experiment in which the activity of aztreonamavibactam in combination with tigecycline was investigated against six isolates. In the time-dependent killing experiment, the combination exerted a synergistic effect against two isolates. Conclusion: Aztreonamavibactam appears to be an important alternative for reversing aztreonam resistance in S. maltophilia. Additionally, tetracyclines, such as tigecycline and doxycycline, are highly effective against these bacteria. To confirm these promising findings, further in vitro, in vivo, and clinical studies are required.

 Background and Aims: Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen that threatens human and public health because of its widespread intrinsic and acquired antibiotic resistance. These bacteria become resistant to aztreonam by degrading it using the beta-lactamases. The aim of this study was to evaluate the effect of aztreonamavibactam on aztreonam resistance in clinical strains of S. maltophilia and to assess the synergistic potential of aztreonam in combination with tigecycline. Methods: Minimum Inhibitory Concentrations MICs of aztreonam, aztreonamavibactam, tigecycline, and doxycycline were determined using broth microdilution in sixty-six S. maltophilia isolates. Additionally, six isolates with the most common MICs of aztreonamavibactam against the strains, 2 μgml and 4 μgml were selected from among the sixty-six tested strains, and the effectiveness of the combination of aztreonamavibactam with tigecycline was determined using both the checkerboard test and the time-dependent killing method. Results: Aztreonamavibactam restored aztreonam activity in 96.9 of resistant S. maltophilia isolates. Half of the isolates were susceptible to tigecycline, whereas all were susceptible to doxycycline. The combination of aztreonamavibactam with tigecycline was found to have an additive effect against all isolates in the checkerboard experiment in which the activity of aztreonamavibactam in combination with tigecycline was investigated against six isolates. In the time-dependent killing experiment, the combination exerted a synergistic effect against two isolates. Conclusion: Aztreonamavibactam appears to be an important alternative for reversing aztreonam resistance in S. maltophilia. Additionally, tetracyclines, such as tigecycline and doxycycline, are highly effective against these bacteria. To confirm these promising findings, further in vitro, in vivo, and clinical studies are required.

Article Details

Efficacy of aztreonam/avibactam against Stenotrophomonas maltophilia alone and in combination with tigecycline

Authors:

Özlem Oyardı | Gülbeyaz Altunboğa | Fatıma Nur Olcay | Zayre Erturan

Publisher:

Istanbul University

Main Topics:

Pharmacology and Pharmaceutical Sciences (Other)

Journal:

İstanbul Journal of Pharmacy Vol.54 Issue 3, pp.395-402

Document Type:

Article

Publication Date:

12/2024

Document Language:

English

Document ID (Org No.):

2001340675

pISSN:

2587-2087

Stenotrophomonas maltophilia

Aztreonam/avibactam

Tigecycline

Combination

Issues

Article Details

Efficacy of aztreonam/avibactam against Stenotrophomonas maltophilia alone and in combination with tigecycline

Authors: Özlem Oyardı | Gülbeyaz Altunboğa | Fatıma Nur Olcay | Zayre Erturan

Publisher: Istanbul University

Main Topics: Pharmacology and Pharmaceutical Sciences (Other)

Journal: İstanbul Journal of Pharmacy Vol.54 Issue 3, pp.395-402

Document Type: Article

Publication Date: 12/2024

Document Language: English

Document ID (Org No.): 2001340675

pISSN: 2587-2087

Stenotrophomonas maltophilia

Aztreonam/avibactam

Tigecycline

Combination

Issues

Authors:

Özlem Oyardı | Gülbeyaz Altunboğa | Fatıma Nur Olcay | Zayre Erturan

Publisher:

Istanbul University

Main Topics:

Pharmacology and Pharmaceutical Sciences (Other)

Journal:

İstanbul Journal of Pharmacy Vol.54 Issue 3, pp.395-402

Document Type:

Article

Publication Date:

12/2024

Document Language:

English

Document ID (Org No.):

2001340675

pISSN:

2587-2087